H2O Plus lapped up by investors
This article was originally published in The Rose Sheet
Executive Summary
Goldman Sachs Urban Investment Group and private equity firm Cordova, Smart & Williams announce acquisition of prestige natural skin-care maker H2O Plus from brand founder Cindy Melk May 29. Investment firms will enjoy joint ownership of the company; Melk will be retained as H2O's chief creative officer. "H2O Plus presented a unique opportunity to invest in a well-positioned, fast-growing brand-name company in the natural and organic personal-care products sector," says Michael Smart, managing partner at CSW. "We believe that aligning our capital and resources with H2O Plus' talented management team will position the company for future growth on a global basis." H2O was founded in 1989; it currently offers about 160 spa, skin-care and bath products in 18 countries, according to release. Brand's international distribution has grown 200% in past two years, and Goldman Sachs and CSW see significant further growth potential in Asia, Europe and Latin America...
You may also be interested in...
Marketing In Brief
NIVEA: Beiersdorf skin-care brand is new multi-year title sponsor for AVP professional beach volleyball tour kicking off April 16 in Fort Lauderdale, Fla., firm announces March 31. All tour events will feature the iconic NIVEA blue color, transforming tournament sites into a "sea of blue," according to the release. NIVEA plans to market its new Happy Sensation body lotion and Touch of Happiness body wash in conjunction with tour events through "advertising, on-site signage, sampling activations, retail activities, PR, contests and online [promotions]," it says. "With its iconic character, its dedication to skin- and body-care worldwide, NIVEA fits perfectly with the health and vitality of our players," notes AVP Commissioner Mike Dodd
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.